Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results